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Expression of the p40 isoform
of p63 has high specificity
for cutaneous sarcomatoid squamous
cell carcinoma
Cutaneous spindle cell malignancies such as sarcomatoid
squamous cell carcinoma (SCC), leiomyosarcoma, desmoplastic
melanoma (DM) and atypical fibroxanthoma (AFX) may be
morphologically indistinguishable, yet accurate diagnosis is
important for appropriate clinical management. The distinction
among these entities relies on immunohistochemical evaluation
for epidermal, muscle or melanocytic differentiation. Epidermal
differentiation markers include cytokeratins and p63. p63 is
expressed as two distinct isoforms, ΔNp63 (p40) and TAp63. p40
positivity is highly specific for pulmonary SCC and head and neck
sarcomatoid SCC. We examined the utility of p40 vs. p63
immunostaining in the differentiation of a variety of cutaneous
spindle cell malignancies, including sarcomatoid SCC (n= 27),
AFX (n= 34) and DM (n= 10). p40 was less sensitive than p63 for
detecting sarcomatoid SCC (56% and 81%, respectively). p63 and
p40 were comparably specific for sarcomatoid SCC relative to
AFX, with only rare weak staining of tumor cells for p63 and/or
p40 in a minority of AFX cases, including one case with
approximately 10% of cells staining weakly for p40. All cases of
DM were negative for p40 and p63. Our results support continued
use of p63 for diagnosis of cutaneous sarcomatoid SCC because of
greater sensitivity relative to p40.
Keywords: atypical fibroxanthoma, deltaNp63, p40, p63, squamous
cell carcinoma
Ha Lan TT, Chen SJT, Arps DP, Fullen DR, Patel RM, Siddiqui J,
Carskadon S, Palanisamy N, Harms PW. Expression of the p40
isoform of p63 has high specificity for cutaneous sarcomatoid
squamous cell carcinoma.
J Cutan Pathol 2014; 41: 831–838. © 2014 John Wiley & Sons A/S.
Published by John Wiley & Sons Ltd
Thanh T. Ha Lan1,
Stephanie J. T. Chen1,
David P. Arps1,
Douglas R. Fullen1,2,
Rajiv M. Patel1,2,
Javed Siddiqui3,
Shannon Carskadon3,
Nallasivam Palanisamy3,4
and Paul W. Harms1,2,3
1Department of Pathology, University of
Michigan Medical School, Ann Arbor, MI
48109, USA,
2Department of Dermatology, University of
Michigan Medical School, Ann Arbor, MI
48109, USA,
3Michigan Center for Translational Pathology,
University of Michigan Medical School, Ann
Arbor, MI 48109, USA, and
4Comprehensive Cancer Center, University of
Michigan Medical School, Ann Arbor, MI
48109, USA
Paul Harms,
Department of Pathology, M3260 Medical
Science I, 1301 Catherine St, Ann Arbor, MI
48109-5602, USA
Tel: +734 764 4460
Fax: +734 764 4690
e-mail: paulharm@med.umich.edu
Accepted for publication August 9, 2014
The classic differential diagnosis of malignant
cutaneous spindle cell neoplasms includes spin-
dle cell or sarcomatoid squamous cell carcinoma
(SCC), atypical fibroxanthoma/superficial
undifferentiated pleomorphic sarcoma (AFX),
desmoplastic melanoma (DM) and leiomyosar-
coma (LMS). The diagnosis is easier when
the lesion displays a more well differentiated
component or an in situ component such as
keratinizing invasive SCC intermingling with
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Table 1. Immunohistochemical expression of cytokeratin (CK), p63 and p40 in atypical fibroxanthoma (AFX) and sarcomatoid squamous cell
carcinoma (S-SCC)
Patient Case Sex Age Location CK performed CK result p63 p40
1 AFX1 M 87 Right lower helix MNF116 Negative Rare (<5%) Negative
2 AFX2 M 81 Left antihelix MNF116, K903 Negative Negative Rare (<5%)
3 AFX3 M 65 Left scalp MNF116, K903 Negative Negative Negative
3 AFX4 M 65 Left scalp MNF116, K903 Negative Negative Rare (<5%)
4 AFX5 M 71 Upper scalp MNF116, K903 Negative Rare (<5%) Negative
5 AFX6 F 47 Right chest MNF116, AE1/AE3 Negative Rare (<5%) Negative
6 AFX7 F 86 Right cheek MNF116, CK cocktail Rare (<5%) (MNF116 only) Rare (<5%) Negative
7 AFX8 M 65 Left scalp MNF116, K903 Negative Negative Negative
8 AFX9 M 76 Right tragus AE1/3, CAM5.2 Negative Negative Negative
8 AFX10 M 74 Right forehead K903, AE1/AE3 Negative Negative Negative
9 AFX12 M 91 Left frontal scalp MNF116 Negative Negative Negative
10 AFX13 M 82 Vertex scalp MNF116 Negative Negative Negative
11 AFX14 M 70 Left upper forehead K903 Negative Negative Negative
12 AFX15 M 72 Left frontal scalp MNF116, AE1/AE3 Negative Negative Negative
13 AFX16 M 70 Left cheek MNF116, CK 5/6 Negative Negative Negative
14 AFX17 M 62 Right parietal scalp MNF116, K903 Negative Negative Rare (<5%)
14 AFX18 M 61 Right lateral scalp MNF116, K903 Negative Negative Negative
15 AFX19 F 28 Supra knee K903 Negative Negative Negative
16 AFX20 M 92 Left parietal scalp CK cocktail Negative Negative Negative
16 AFX21 M 92 Left parietal scalp K903 Negative Negative Negative
17 AFX22 M 74 Upper forehead MNF116, K903 Negative Negative Negative
18 AFX23 M 91 Left concha MNF116, K903 Negative Negative Negative
19 AFX24 M 72 Right temple MNF116, CK cocktail Negative Negative Negative
19 AFX25 M 72 Right temple MNF116, CK cocktail Negative Rare (<5%) Negative
20 AFX26 M 68 Left antihelix MNF116, CK cocktail Negative Negative Negative
21 AFX27 M 81 Left posterior scalp MNF116, K903 Negative Negative Negative
22 AFX28 M 85 Left cheek CK Negative Negative Negative
23 AFX29 F 83 Left neck MNF116, AE1/AE3 Negative Negative Negative
24 AFX30 M 83 Right vertex scalp MNF116 Negative Negative Negative
25 AFX31 M 69 Posterior crown scalp MNF116, K903 Negative Negative Negative
26 AFX32 M 68 Left conchal bowl MNF116, AE1/AE3 Negative Negative Negative
27 AFX33 M 87 Vertex scalp AE1/AE3, CAM5.2 Negative Negative Negative
28 AFX34 M 84 Right scalp vertex CK cocktail, CK5/6 Negative Negative Negative
29 S-SCC1 M 72 Left preauricular K903, AE1/AE3 Negative Positive Negative
30 S-SCC2 M 83 Left temple MNF116, K903 Negative Positive Negative
30 S-SCC3 M 85 Left temple K903, CK cocktail Negative Positive Negative
31 S-SCC4 M 65 Left cheek MNF116 Negative Positive Positive
32 S-SCC5 M 80 Vertex scalp MNF116, CK5/6 Negative Positive Negative
32 S-SCC6 M 80 Vertex scalp MNF116, CK5/6 Negative Positive Rare (<5%)
33 S-SCC7 M 64 Left lower lip MNF116 Positive Positive Positive
34 S-SCC8 M 69 Left forehead MNF116, K903 Positive Positive Positive
35 S-SCC9 M 75 Right face CK5/6, K903 Positive Positive Positive
36 S-SCC10 M 91 Left ear K903 Positive Positive Positive
37 S-SCC11 F 79 Back CK Positive Positive Positive
38 S-SCC12 M 80 Left forearm K903 Positive Positive Positive
38 S-SCC13 M 81 L. epitrochlear node
(metastasis)
Not performed (met from
S-SCC12)
NA Positive Positive
39 S-SCC14 M 70 Left back K903 Positive Positive Positive
40 S-SCC15 M 79 Scalp MNF116 Positive Positive Positive
41 S-SCC16 F 50 Left eyelid MNF116, AE1/AE3,CAM5.2 Positive Positive Positive
42 S-SCC17 M 76 Right ear K903 Positive Positive Positive
43 S-SCC18 M 67 Right ear helix MNF116, K903 Positive Positive Positive
44 S-SCC19 F 85 Right ear Not performed (co-existing
conventional component)
NA Positive Positive
45 S-SCC20 M 58 Left forehead Not performed (SCC
recurrence)
NA Positive Positive
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Table 1. Continued
Patient Case Sex Age Location CK performed CK result p63 p40
46 S-SCC21 F 84 Left frontal
scalp/forehead
MNF116 Positive Positive Rare (<5%)
47 S-SCC22 F 61 Chin MNF116, K903, CK cocktail Negative Positive Negative
48 S-SCC23 M 81 Right temple MNF116, K903, CK5/6 Positive (MNF116
only)
Rare (<5%) Rare (<5%)
49 S-SCC24 M 64 Right preauricular MNF116 Positive Negative Negative
50 S-SCC25 F 49 Chest Not performed (co-existing
conventional component)
NA Negative Negative
51 S-SCC26 M 92 Right posterior helix MNF116, CK cocktail Positive Rare (<5%) Negative
51 S-SCC27 M 92 Ear MNF116, CK cocktail Positive (MNF116
only)
Negative Negative
a sarcomatoid SCC ormelanoma in situ overlying
a DM, respectively. More commonly, the distinc-
tion among these entities relies on the expres-
sion of immunohistochemical markers in sup-
port of a specific line of differentiation.
One of the most reliable markers for sarco-
matoid SCC is p63,1–3 a member of the TP53
gene family. p63 is essential for the development
of limbs, craniofacial structures and squa-
mous epithelia including associated adnexal
structures.4,5 p63 expression is highly specific
for squamous epithelium,6–10 but p63 is also
expressed in normal basal cells, myoepithelial
cells, trophoblasts, thymic epithelium11 and
urothelium. Some non-squamous neoplasms
also express p63, including some lymphomas12;
a small number of sarcomas13; and adenocar-
cinomas from the lung,10,14–17 gastrointestinal
and gynecologic tract.
The p63 gene product consists of two primary
isoforms, TAp63 and ΔNp63, which differ only
in their N-terminal domain.18 Interestingly, these
two isoforms have opposing functions. TAp63
acts as a tumor suppressor in a manner similar to
p53, while ΔNp63 antagonizes both TAp63 and
p53 in a manner analogous to an oncogene.18
ΔNp63 is preferentially expressed in the basal
cells of stratified epithelium, where it is believed
to confer ‘stem cell’ properties.19–21
The most routinely used anti-p63 antibody,
4A4, does not distinguish between the differ-
ent p63 isoforms; whereas the anti-p40 anti-
body specifically recognizes the ΔNp63 isoform.
Anti-p40 has gained diagnostic application in
the past several years, most notably in the set-
ting of lung carcinoma where it is used to
distinguish pulmonary SCC from pulmonary
adenocarcinoma.22 Anti-p40 is also used to dif-
ferentiate head and neck sarcomatoid SCC from
mesenchymal neoplasms.22,23
Because ΔNp63 is highly expressed in SCC
and knowledge of differences between p63 and
p40 expression in different cutaneous spindle
cell tumors is largely unknown, this study was
undertaken to assess the utility of p40 vs. p63 in
diagnosing cutaneous sarcomatoid SCC relative
to AFX, DM and other frequently encountered
cutaneous spindle cell neoplasms.
Methods
Case selection and tissue microarray construction
The study was approved by the Institutional
Review Board at the University of Michigan
Fig. 1. p40 expression in conventional squamous cell carcinoma (A) and normal skin (B) (hematoxylin and eosin, ×100
magnification).
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Table 2. Expression of p40 and p63 in dermal spindle cell neoplasms and reactive mimics
p40 p63
Diagnosis n Negative (<5%) Positive Negative (<5%) Positive
Spindle cell malignancies
Sarcomatoid squamous cell carcinoma 27 12 (44%) 15 (56%) 5 (19%) 22 (81%)
Atypical fibroxanthoma 34 34 (100%) 0 (0%) 34 (100%) 0 (0%)
Undifferentiated pleomorphic sarcoma 9 6 (67%) 3 (33%) 9 (100%) 0 (0%)
Desmoplastic melanoma 10 10 (100%) 0 (0%) 10 (100%) 0 (0%)
Leiomyosarcoma 4 4 (100%) 0 (0%) 4 (100%) 0 (0%)
Dermatofibrosarcoma protuberans 10 10 (100%) 0 (0%) 10 (100%) 0 (0%)
Benign mesenchymal lesions
Dermatofibroma, conventional 6 6 (100%) 0 (0%) 6 (100%) 0 (0%)
Dermatofibroma, lipidized 1 1 (100%) 0 (0%) 1 (100%) 0 (0%)
Dermatofibroma, hemosiderotic 2 2 (100%) 0 (0%) 2 (100%) 0 (0%)
Dermatofibroma, cellular 4 4 (100%) 0 (0%) 4 (100%) 0 (0%)
Epithelioid fibrous histiocytoma 7 7 (100%) 0 (0%) 7 (100%) 0 (0%)
Dermatomyofibroma 5 5 (100%) 0 (0%) 5 (100%) 0 (0%)
Superficial acral fibromyxoma 2 2 (100%) 0 (0%) 2 (100%) 0 (0%)
Cellular neurothekeoma 1 1 (100%) 0 (0%) 1 (100%) 0 (0%)
Leiomyoma 9 9 (100%) 0 (0%) 9 (100%) 0 (0%)
Neurofibroma 10 10 (100%) 0 (0%) 10 (100%) 0 (0%)
Histiocytic lesions
Xanthoma 3 3 (100%) 0 (0%) 3 (100%) 0 (0%)
Juvenile xanthogranuloma 5 5 (100%) 0 (0%) 5 (100%) 0 (0%)
Reticulohistiocytoma 2 2 (100%) 0 (0%) 2 (100%) 0 (0%)
Rosai-Dorfman 1 1 (100%) 0 (0%) 1 (100%) 0 (0%)
Langerhans cell histiocytosis 1 1 (100%) 0 (0%) 1 (100%) 0 (0%)
Fig. 2. Immunohistochemical expression of p40 and p63 in atypical fibroxanthoma (AFX). All AFX in this study lacked significant
expression of p40 (A), although a minority of cases displayed faint cytoplasmic ‘blush’ (B). The same AFX cases displayed
weak-moderate staining with p63 (C and D) (×200 magnification).
Health System and was carried out in accordance
with the guidelines for human subject research.
The study includes previously constructed
tissue microarrays (TMAs) representing a
spectrum of primary cutaneous epithelial
neoplasms, cutaneous spindle cell tumors,
histiocytic/fibrohistiocytic lesions and their
microscopic mimics.24 In addition to TMAs,
whole tissue sections of sarcomatoid SCC, DM
and additional AFX cases were identified by a
retrospective search of the pathology archives
at the University of Michigan, Department of
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Pathology from 2004 to 2013. Hematoxylin and
eosin-stained sections and a subset of previously
performed immunohistochemical stains were
reviewed for diagnosis confirmation by two
pathologists (P.W.H. and T.T.H.L.).
Immunohistochemistry
Unstained slides from the TMAs and conven-
tional paraffin blocks were stained with p40
and p63 antibody. Briefly, 4-uM-thick unstained
sections were pretreated with Ventana CC1 Solu-
tion (pH8.0) for antigen retrieval and were incu-
bated with mouse monoclonal anti p63 anti-
body (clone 4A4, predilute; Ventana Medical
Systems, Tucson, AZ, USA), and rabbit poly-
clonal anti p40 antibody (clone 5-17, 1:8000 dilu-
tion; Calbiochem, Darmstadt, Germany) using a
Ventana Benchmark XT system (Ventana Med-
ical Systems). The UltraVision System and a
3,3′-diaminobenzidine chromogen were used for
detection. Staining conditions for p40 were val-
idated on pulmonary SCC (n= 2) and nor-
mal epidermis with pulmonary adenocarcinoma
(n= 2) as negative controls. Nuclear staining in
at least 5% of lesional cells was considered pos-
itive for p63 and p40. The distribution of posi-
tivity (restricted to the basal layer or diffuse) was
also noted.
Results
Our study cohort included a total of 34 cases of
AFX (from 28 patients), 27 cases of sarcomatoid
SCC (from 23 patients) and 10 cases of DM
(from 10 patients). These included two cases of
AFX which were re-classified as sarcomatoid SCC
upon review of immunohistochemical profiles.
DM cases included seven pure desmoplastic
melanomas, two melanomas with predomi-
nantly desmoplastic features and a co-existing
component of spindled melanoma and one
desmoplastic melanoma with a focal area with
sarcomatoid appearance. Clinical features and
immunohistochemical profiles of AFX and
sarcomatoid SCC cases are presented in Table 1.
p40 antibody was validated in direct com-
parison with p63. Positive controls included
pulmonary SCC (n= 2), cutaneous SCC (n= 8)
and hypertrophic lichen planus (n= 4). Nega-
tive controls were pulmonary adenocarcinoma
(n= 2). p40 was positive with moderate stain-
ing intensity in 100% of pulmonary SCC and
conventional cutaneous SCC and negative in
both cases of pulmonary adenocarcinoma.
p40 showed the same distribution of positivity
although weaker nuclear intensity compared
to p63. Cutaneous SCCs displayed basal layer
staining in well-differentiated tumors (Fig. 1A)
Fig. 3. Immunohistochemical expression of p40 and p63 in cutaneous sarcomatoid squamous cell carcinoma (sarcomatoid SCC).
A) Sarcomatoid SCC with diffuse strong p40. B) Sarcomatoid SCC with moderate p40 expression. C and D) Strong p63 expression
in both tumors (×200 magnification).
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or diffuse staining in less-differentiated tumors.
We also evaluated normal skin and found sim-
ilar expression patterns of p40 and p63 with
basal staining of the epidermis and adnexal
epithelium (Fig. 1B).
The majority of studies to date show absent or
only focal p63 and CK expression in AFX.1,25–27
Thus, we set the threshold for significant p63
and CK expression as weak to strong immuno-
labeling in ≥5% of lesional cells. p63 and p40
immunolabeling was performed in parallel.
All AFX cases lacked significant p40 and p63
expression (Tables 1 and 2, Fig. 2). A few of the
cases scored as negative showed rare cells (<5%)
immunoreacting to p40 (n= 3) and p63 (n= 4)
(Fig. 2B).
Significant p40 expression was seen in 55.6%
of sarcomatoid SCC (n= 15) whereas 81.5% of
sarcomatoid SCC (n= 22) were positive for p63
(Tables 1 and 2, Fig. 3). An additional two cases
(7.5%) showed moderate p40 labeling in <5%
of lesional cells, which did not reach this study’s
threshold for positivity. For sarcomatoid SCC,
p40 and p63 labeling were concordant in 74% of
cases. Fifteen cases showed dual positivity while
five cases showed dual negativity. The remaining
seven cases (26%) showed significant staining
for p63 but not p40. Interestingly, in six of
these seven cases, CK stains were also negative.
In the remaining p63+/p40− sarcomatoid SCC
case, CK was positive and p40 weakly stained rare
cells (below the threshold considered positive).
Notably, the lesion was not highly cellular and
this discrepancy could be a result of intratumoral
heterogeneity. CK and p40 showed concordant
results in 73% of cases.
We further compared p40 and p63 expression
in additional benign and malignant cutaneous
spindle cell lesions (Table 2). These included
nine cases of cutaneous undifferentiated pleo-
morphic sarcoma (also known as pleomorphic
dermal sarcoma), defined as spindle cell malig-
nancies that lack expression of lineage markers
such as cytokeratin, and that are not classified
as AFX because of the presence of necrosis,
lymphovascular invasion, perineural invasion,
large size or significant subcutaneous extension.
Three of nine (33%) cases of undifferenti-
ated pleomorphic sarcoma displayed nuclear
expression of p40 in 5–10% of tumor cells.
Interestingly, these lesions did not show signifi-
cant staining with p63. p40 and p63 were nega-
tive in all of the remaining dermal spindle cell
neoplasms and histopathologic mimics,
including all cases of DM (n= 10) (Table 2,
Fig. 4).
Fig. 4. Immunohistochemical expression of S100 and p40 in
desmoplastic melanoma. A) S100 is strongly and diffusely
positive. B) Absence of p63 expression. C) The same case lacks
p40 expression (×200 magnification).
We also examined p40 and p63 expression in a
small number of cutaneous histiocytic lesions. As
expected, both p40 and p63 were negative in all
cases (Table 2).
Discussion
Poorly differentiated cutaneous spindle cell
neoplasms, including desmoplastic melanoma,
sarcomatoid SCC and AFX, vary greatly in
836
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clinical outcome but may be impossible to
reliably distinguish on morphologic grounds.
Therefore, immunohistochemical stains play
an important role in the differential diagnosis
of these poorly differentiated neoplasms. In
addition to cytokeratin, p63 is frequently used
to identify or confirm squamous cell differentia-
tion. The most commonly used antibody to p63
recognizes both the ΔNp63 and TAp63 isoforms
of the p63 gene product. The polyclonal anti-p40
antibody used in this study is specific for the
ΔNp63 isoform, which possesses oncogene-like
properties. This antibody has been shown to
have superior specificity for pulmonary SCC
relative to the commonly used p63 antibody.
However, the expression of p40 in primary cuta-
neous neoplasms is not well understood and
the utility of the anti-p40 antibody in recogniz-
ing cutaneous sarcomatoid SCC has not been
established.
This study shows that p40 expression is similar
to p63 in normal skin structures and cuta-
neous spindle cell tumors. Specifically, p40 is
consistently expressed in non-neoplastic skin
including normal epidermis, adnexal structures
and reactive epidermal conditions including
hypertrophic lichen planus. In addition to AFX,
p40 is also consistently negative in other tumors
of fibrohistiocytic, fibroblastic or smooth muscle
differentiation, with the exception of positive
cells in some cases of undifferentiated pleo-
morphic sarcoma. As observed in this study
and noted in other studies with regards to
p63, a small subset of AFX cases displayed rare
tumor cells (<5%) with weak nuclear expression
for p40 and/or p63 not reaching the study’s
threshold for significance (Table 1). In these
cases of rare focal staining, p40 and p63 were
sometimes but not consistently co-expressed,
possibly reflecting intratumoral heterogeneity.
By our criteria for significant expression, p40
was relatively specific for sarcomatoid SCC rel-
ative to AFX and undifferentiated pleomorphic
sarcoma (93.0%).
Although highly specific, p40 displayed lim-
ited sensitivity for sarcomatoid SCC (55.6%)
(Table 2). The expression of p40 mirrors
closely that of CKs. Specifically, five of six
sarcomatoid SCC that lacked significant cytok-
eratin expression also lacked p40 expression,
despite significant p63 expression (Table 1).
Cytokeratin-negative/p63-positive cutaneous
spindle cell tumors are poorly described in the
literature. However, sarcomatoid SCC arising
in mucosal sites may lose cytokeratin expres-
sion yet retain p63 expression28 and a similar
phenomenon is likely to occur in cutaneous
sarcomatoid SCC. To our knowledge, loss of p40
isoform expression with retained p63 expres-
sion (presumably TAp63 isoform) has not been
extensively described. Further investigation
is needed to determine whether cutaneous
cytokeratin-negative/p40-negative/p63-positive
tumors display differences in biology or clinical
behavior relative to other sarcomatoid SCC.
In conclusion, p40 is a highly specific but
less sensitive marker for sarcomatoid SCC com-
pared to p63. This result suggests that p40 is use-
ful, however not interchangeable with p63 in a
diagnostic immunohistochemical stain panel for
cutaneous spindle cell malignancies.
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